Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00566202 | A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression | PHASE2 | COMPLETED | 67 | — | — | Dec 1, 2007 | Dec 1, 2008 | Aug 6, 2014 | 26 | United States |
| Arm | Type | Description |
|---|---|---|
| JNJ-18038683 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Escitalopram | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Form= capsule, route= oral use. Administration once daily for 8 weeks. |
| Escitalopram | DRUG | Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week. |
| JNJ-18038683 | DRUG | Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week. |
Inclusion Criteria: * Diagnosed with moderate to severe major depressive disorder * Willing to use acceptable methods of birth control throughout the study and for 3 months after * In good general health Exclusion Criteria: * No history or current diagnosis of other psychiatric conditions such as...